Gene Therapy Clinical Trials
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
This clinical trial is studying the side effects of Erwinia asparaginase and what happens to the drug in the body in treating young patients with acute lymphoblastic leukemia who are allergic to PEG-asparaginase. Drugs used in chemotherapy, such as Erwinia asparaginase, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: laboratory biomarker analysis
- other: pharmacological study
- drug: asparaginase
Eligibility
Inclusion Criteria:
- Diagnosis of acute lymphoblastic leukemia
- Concurrently enrolled on a frontline Children's Oncology Group treatment trial (i.e.,
COG-AALL0232 or COG-AALL0531, COG-AALL0331, or COG-AALL0434) at a participating
institution
- Must have 1 or more courses of asparaginase remaining to be administered on the
treatment protocol
- Must have had a grade ? 2 hypersensitivity reaction to PEG-asparaginase
- No history of pancreatitis ? grade 2
- No prior Erwinia asparaginase
Ages Eligible for Study
1 Year - 30 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting